Your browser is no longer supported. Please, upgrade your browser.
PCSA Processa Pharmaceuticals, Inc. daily Stock Chart
Processa Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.07 Insider Own16.00% Shs Outstand5.59M Perf Week22.61%
Market Cap50.82M Forward P/E- EPS next Y-0.51 Insider Trans2.13% Shs Float4.24M Perf Month35.25%
Income-6.00M PEG- EPS next Q-0.55 Inst Own10.65% Short Float0.15% Perf Quarter-33.65%
Sales- P/S- EPS this Y0.90% Inst Trans- Short Ratio0.16 Perf Half Y-66.43%
Book/sh0.99 P/B5.70 EPS next Y19.00% ROA-58.90% Target Price- Perf Year-76.30%
Cash/sh0.03 P/C169.39 EPS next 5Y- ROE-87.10% 52W Range3.40 - 18.00 Perf YTD-68.67%
Dividend- P/FCF- EPS past 5Y29.80% ROI- 52W High-68.67% Beta-0.52
Dividend %- Quick Ratio0.10 Sales past 5Y- Gross Margin- 52W Low65.88% ATR0.30
Employees13 Current Ratio0.10 Sales Q/Q- Oper. Margin- RSI (14)57.76 Volatility10.68% 5.52%
OptionableNo Debt/Eq0.31 EPS Q/Q-252.40% Profit Margin- Rel Volume0.24 Prev Close5.40
ShortableYes LT Debt/Eq0.02 EarningsNov 12 AMC Payout- Avg Volume39.16K Price5.64
Recom2.00 SMA2026.50% SMA501.89% SMA200-58.63% Volume9,211 Change4.44%
Nov-16-20 12:48PM  
Nov-12-20 05:02PM  
Nov-05-20 09:15AM  
Nov-03-20 09:20AM  
Oct-13-20 09:30AM  
Oct-07-20 09:25AM  
Oct-06-20 04:05PM  
Oct-02-20 06:00AM  
Aug-27-20 09:30AM  
Aug-20-20 09:30AM  
Jun-01-20 09:30AM  
Mar-30-20 04:00PM  
Mar-17-20 09:30AM  
Mar-05-20 09:30AM  
Feb-25-20 09:30AM  
Feb-13-20 09:30AM  
Dec-20-19 04:10PM  
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops drugs for the unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase II clinical trials for the treatment of necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase II clinical trials for the treatment of post-operative ileus; and PCS6422, an oral, potent, selective, and irreversible inhibitor that is in Phase I clinical trials for treating metastatic colorectal and breast cancer. It also has license agreement with Akashi Therapeutics, Inc. to develop and commercialize PCS100, an anti-fibrotic and anti-inflammatory drug. The company was founded in 2015 and is based in Hanover, Maryland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BESSER JAMES E10% OwnerOct 02Buy4.0430,000121,200405,000Oct 13 06:33 PM
affiliate | advertise | contact | privacy | help
Do not sell my personal information

Quotes delayed 15 minutes for NASDAQ, and 20 minutes for NYSE and AMEX.
Copyright © 2007-2020 All Rights Reserved.